Abstract Visceral adipose inflammation mediated by innate and adaptive immune alterations plays a critical role in diet-induced obesity and insulin resistance (IR). The dietary supplement a-lipoic acid (aLA) has been shown to ameliorate inflammatory processes in macrophages, however the relative significance of these effects in the context of visceral adipose inflammation and IR remain unknown. In this study we investigated its effects via both intraperitoneal and oral administration in lean and obese transgenic mice expressing yellow fluorescent protein (YFP) under control of a monocyte specific promoter (c-fms YFP?
). aLA significantly improved indices of insulin-resistance concomitant with a decrease in total (YFP ) visceral adipose tissue macrophages. Histologically, the visceral adipose tissue of obese mice receiving aLA had fewer ''crown-like structures,'' a hallmark of adipose inflammation in murine obesity. Monocyte adhesion assessed by intravital microscopy of cremasteric venules was attenuated by aLA. In cultured WT and toll-like receptor 4 (TLR4) null primary mouse macrophages, aLA significantly decreased basal CCR-2, MCP-1 and TNF-a expression levels. LPS treatment resulted in increased TNFa, MCP-1, and IL-6 expression while aLA partially abrogated the LPS effect on MCP-1 and TNFa; Interestingly, CCR-2 was not coordinately regulated. AaLA prevented LPS-induced nuclear factor kappa B (NFjB) activation in the same cultured macrophages. These data suggest that aLA may modulate visceral adipose inflammation, a critical determinant of IR via TLR4 and NF-jB pathways.
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Introduction
A large body of evidence links inflammation to the development of insulin resistance (IR) in type 2 diabetes mellitus and obesity [1, 2] . Adipose tissue in both disorders is typified by a dramatic remodeling of adipose and stereotypic alterations in the numbers and function of macrophage and dendritic cells in visceral fat [2] [3] [4] . Inflammation in visceral adipose tissue is thought to play a central role, with the degree of inflammation being demonstrated to inversely correlate with insulin sensitivity [5] [6] [7] [8] . Conversely, treatment of inflammation has been shown to reverse insulin resistance and improve indices of whole body glucose homeostasis. The mechanisms by which a dysregulated immune axis may contribute to IR is multifactorial but a key pathway is through the release of pro-inflammatory cytokines (TNFa and IL-6), and immunoattractant chemokines that further contribute to an adaptive immune response [9] [10] [11] [12] [13] [14] [15] [16] . Mice that lack TNFa and CCR-2, the receptor for monocyte chemoattractant protein 1 (MCP-1/CCL-2), have improved insulin sensitivity and glucose metabolism when compared to adiposity-matched controls [13, 17] . Recent studies show that the Toll-like receptor 4 (TLR4) may play a central role in the link among insulin resistance, inflammation, and obesity; TLR4 deficiency prevented insulin resistance and obesity-mediated activation of IjB kinase (IKKb) and c-Jun NH2-terminal kinase (JNK), suggesting that TLR4 is a key modulator in the cross-talk between inflammatory and metabolic pathways [18] [19] [20] [21] [22] . Alpha lipoic acid (aLA) is a disulfide derivative of octanoic acid that forms an intra-molecular disulfide bond that is readily reduced to dihydrolipoic acid intra-cellularly [23] . Anorectic effects in rodents have been reported for aLA as well as improved hypertriglyceridemia in Zucker diabetic fatty rats [24] . aLA has been reported to increase insulin sensitivity in the skeletal muscle via AMPK activation in obese rats [25] though other researchers have failed to confirm this finding [24] . aLA has been shown to reduce NF-jB activation in human monocytic cells and reduce inflammation [26] . However the impact of aLA on innate immune inflammation and whether these effects lead to coordinate change in indices of IR/glucose homeostasis have not been investigated. We employed a novel model of diet-induced obesity/IR using transgenic reporter mice that express YFP under control of a c-fms reporter (c-fms YFP? ) that allows monocyte specific expression of the reporter and unparalleled ability to track these cells in visceral adipose tissue. In carefully performed pair-fed experiments, we demonstrate that aLA improves key metrics of innate immune activation and IR.
Materials and Methods

Animals
Oral aLA Regimen c-fms YFP? transgenic mice were generated at the Transgenic Animal Service of Queensland, Brisbane, Queensland, Australia by injection of the transgenes into pronuclei of (C57BL/6 9 CBA)F 1 (BCBF1) fertilized eggs [27] . The Committee on Use and Care of Animals from the Ohio State University (OSU) approved all experimental procedures. c-fms YFP? mice of the FVB/N strain were bred and genotyped at OSU and housed in cages individually. YFP ? males at 6 weeks of age were fed a HFD for 8 weeks (42% energy from fat-Harlan Teklad TD88137) prior to randomized to three dietary groups (5 mice/group): ad libitum, aLA-fed, and pair-fed to aLA. Pair-feeding was employed as aLA is well known to modulate central appetite pathways and reduce food intake. Food intake was monitored every other day by weighing the remaining chow; pair-fed mice were then offered the same amount of food as consumed by the aLA-mice. aLA (2 mg/ml; Sigma Aldrich T5625) was administered in the drinking water (ultrapure 18.2 MX) at a pH of 8.0 with NaOH. Pair-fed mice were given ultrapure water at a pH of 8.0. aLA was administered for 8 weeks before mice were sacrificed. Mice consumed approximately 6 mg of aLA per day over the course of the study, which was a dose of 167 mg/kg at time zero, and 157 mg/kg after 8 weeks due to weight gain.
Determining an appropriate oral aLA dose was challenging as there were no published data on plasma aLA levels in mice after oral administration. Thus, we used a dose previously shown to be effective in mice on disease processes, that did not have adverse side effects, and which was reasonable in regards to what plasma levels might be expected. Yi and Maeda [28] used approximately 200 mg/ kg via addition to the chow and showed significant abrogation of atherosclerotic lesion development. Additionally, if one considers 50 mg/kg injections in mice resulted in modest plasma levels of 7.6 ± 1.4 lg/ml [29] , the oral dose of *160 mg/kg used in this study is expected to result in \7 lg/ml plasma concentrations due to bioavailability limits and gastrointestinal metabolism.
IP aLA Regimen
Males at 6 weeks of age were fed a HFD for 8 weeks, before being randomized to aLA or vehicle control groups. A solution of sterile aLA in saline (4 mg/ml) was injected intraperitoneally at a dose of 10 mg/kg once daily, 6 days a week. Mice were weighed daily to ensure accurate dosing. aLA dosing in the mouse was done with attention to the concentration reasonably obtained in human plasma by use of conventional dietary supplements. Healthy human subjects given an average oral dose of 8.25 mg/kg (600 mg) of R-aLA sodium salt dissolved in water were shown to have a mean maximum plasma concentration (C max ) of 16.03 lg/ml [30] . However, others have reported a much lower oral bioavailability, with 600 mg of racemic aLA via solid supplement resulting in a C max of 2.85 [31] and 2.7 lg/ml [32] . These data suggest that potassium or sodium salt of lipoic acid have higher oral bioavailability, as was administered in this study. Additionally, a human oral dose of 1,200 mg resulted in plasma C max levels of 3.8 ± 2.6 to 10.3 ± 3.8 lg/ml with area under the curve (AUC) levels from 443.1 ± 283.9 to 848.8 ± 360.5 which was similar to a subcutaneous injection of 50 mg/kg aLA in mice which yielded 7.6 ± 1.4 lg/ml and 223 ± 20 AUC [29] . The dose of 10 mg/kg (daily) and 50 mg/kg (acute) used in this report are reasonable if not conservative in this context.
Serum Cytokine Analysis
Blood was collected via heart puncture under CO 2 anesthesia and allowed to coagulate at room temperature followed by centrifugation. Serum cytokine levels were analyzed using BD TM Cytometric Bead Array, Mouse inflammation kit according to the manufacturer instructions.
Epididymal Fat Pad Digestion and Quantification of ATMs
Epididymal fat pads from c-fms YFP? mice at the end of the treatment phase were excised, minced, washed in 19 PBS, and digested with sterile collagenase type II from Clostridium histolyticum (1 mg/ml) in DMEM (10% FBS) at 37°C with shaking (140 rpm) as detailed previously [4, 33] . The digesta was filtered through a 100 lm nylon cell strainer before centrifugation (3009g, 10 min). The resulting pellet was defined as the stromal vascular fraction (SVF). Viable adipose tissue mononuclear cells were isolated from SVF using Lympholyte M (Cedarlane Laboratories Ltd, Burlington, NC). Approximately 10 6 cells were incubated with mouse FcR blocking reagent (Miltenyi Biotec Inc., Auburn CA) in FACS buffer (19 PBS, 5% FBS) for 10 min at 4°C followed by staining with F4/80-PE-Cy5, CD11b-PE, and isotype control antibodies (Biolegend, San Diego, CA). Cells were washed in FACS buffer 3 times and measured (BD FACS LSR II TM flow cytometer, Becton-Dickinson, San Jose, CA). Data were analyzed using BD FACS Diva 6.0.1 software (BectonDickinson, San Jose, CA). Gates were set using the appropriate isotype controls.
Live Confocal Microscopy of Unfixed Adipose Tissue
Epididymal fat was removed using sterile techniques and carefully cut into *3-4 mm pieces. After rinsing with 19 PBS the tissue was incubated with Griffonia simplicifolia isolectin GS-IB4 conjugated to AlexaFluor 488 (10 lg/mlMolecular Probes), BODIPY 558/568 (5 lM-Molecular Probes), and Hoechst 33342 (40 lM-Molecular Probes) for 1 h in 19 PBS supplemented with 1 mM CaCl 2 . Isolectin has been shown to be an endothelial cell specific stain in the adipose [34] . Tissue was visualized on a Zeiss laser scanning microscope 510 under 409 water immersion.
Monocyte-Vascular Adhesion as Assessed by Intravital Microscopy
Mice were given aLA IP (50 mg/kg body weight) 24 h before the start of the experiment. TNFa was injected IP (1 lg/kg; 0.9% saline with 1.0% BSA) 4 h before visualization. Under ketamine/xylazine anesthesia, the testicular cremaster muscle was exposed using a dissecting microscope (29; Nikon SMZ 645, Japan). The cremaster muscle was bathed with Ringers Lactate at 37°C and monocyteendothelial interaction was assessed in 15-25 vessels using a Nikon Eclipse FN1 microscope (Nikon, Japan) with a 409/0.80 W water immersed objective at a 2.0 mm working distance. In all experiments video images were captured and digitalized to 12-bit TIF images using Metamorph software (version 7.1.2.0, Metamorph, Downingtown, USA). Rolling YFP ? cells were counted per minute for different vessel diameters and vessel segments. All YFP ? cells, per 100 lm of vessel length, that were immobile for at least 30 s were interpreted as adherent cells [35] . Calculations to determine the number of rolling and adherent cells according to vessel diameter were performed using Opti Test (Version 1.4.1.0).
Bone Marrow Derived Macrophage Culture and Differentiation
Bone marrow was isolated from WT or TLR4 deficient mice and grown in DMEM media supplemented with 10% FBS in the presence of L-cell conditioned media for 5 days. The differentiated macrophages were pretreated with aLA (100 lg/ml) 45 min before LPS (0.5 lg/ml) addition. Post absorption, aLA is rapidly cleared from circulation via renal excretion and tissue uptake. While much is excreted, tissues especially the liver, heart, skeletal muscle, and possibly the brain, accumulate aLA and extensively catabolize to a dozen or more metabolites depending on species [36, 37] . There is also evidence the aLA is rapidly reduced by cells in vitro to DHLA and subsequently excreted [37] . Thus, determining in vitro doses that might be physiologically relevant was challenging. 100 lg/ml (*0.5 mM) aLA was previously shown to prevent LPS-induced TNFa expression in mouse monocytes in vitro and was found to be an optimal dose for Akt phosphorylation [38] . This does is higher than would be obtained in mouse serum, thus it most likely superphysiological but is no more than tenfold higher than what is possible in serum. Also, relative to published in vitro studies using aLA the dose used herein is conservative [39, 40] .
Quantitative-Real-Time PCR Detection of Macrophage Activation Status RNA was isolated using Absolutely RNA Ò , Stratagene TM according to the manufacturer's instructions including DNase digestion. RNA quality and quantity were assessed by agarose gel electrophoresis and a Nanodrop TM spectrophotometer. cDNA was reverse transcribed using 800 ng of total RNA according the manufacturer's instructions (Invitrogen Life Technologies-M-MLV reverse transcriptase) using random primers. PCR was performed using SYBR Green I master mix (Roche) on a Roche Lightcycler 480. All real-time reactions had the following profile conditions: 10 min hot start at 95°C followed by 45 cycles of 94°C 10 s, 60°C 20 s, 72°C 20 s. Reference and target gene dilution standards were run in triplicate for each primer set to calculate PCR efficiency using the above profile. The concentration ratios were determined after PCR efficiency correction by relative quantification analysis using Lightcycler 480 software. All target genes were expressed as fold increase compared to control. Melting/dissociation curves were run on each plate to assure the production of one amplicon of the same melting temperature for each primer set. Real time primers (listed below) were designed to span genomic introns, thus avoiding amplification of genomic DNA possibly present in the RNA samples. ''No template,'' cDNA negative controls were included for each gene set in all PCR reactions to detect contamination. Primers used were: TNFa For 5
Chemiluminescent Electrophoretic Mobility Shift Assay
Nuclear extracts for use in EMSAs were performed using the previously published protocol [41, 42] . Oligonucleotides probes (NFjB sense 5 0 -AGTTGAGGGGACTT TCCCAGGC-3 0 , NFjB antisense 5 0 -GCC TGG GAA AGT CCC CTC AAC T-3 0 ) were biotinylated using Biotin 3 0 End DNA Labeling Kit (Pierce, Rockford IL #89818) according to manufacturer's instructions. Lightshift TM Chemiluminescent EMSA kit (Peirce, Rockford IL #20148) was used to perform the binding reaction and chemiluminescent detection. Briefly, 5 lg of nuclear extract was incubated at room temperature in a binding reaction which included a final concentration of: 19 binding buffer, 50 ng/ll Poly (dIÁdC), 0.05% NP-40, 2.5% glycerol, and 5 mM MgCl 2 for 15 min prior to addition of the biotinylated probes. The complex was run on a pre-electrophoresed 6% polyacrylamide gel in 0.59 TBE (pH 8.4) at 100 V for approximately 45 min followed by wet-transfer in 0.59 TBE to Amersham Hybond TM -N? membrane (GE Healthcare) at 380 mA for 30 min. The transferred DNA was cross-linked to the membrane before continuing with protocol according to manufacturer's instructions. X-ray film was exposed to membrane and developed.
Results
Alpha Lipoic Acid (ala) Administration Improved Markers of Systemic and Local Insulin Sensitivity and Triacylglycerol Metabolism
Oral aLA Regimen At the end of 8 weeks of HFD feeding, c-fms YFP? transgenic mice were markedly insulin resistant demonstrating evidence of fasting hyperglycemia and hyperinsulinemia. Body weight increased approximately 16 g. Following this period mice were assigned to ad libitum treatment (aLA 2 mg/ml drinking water), or pair-fed groups. c-fms YFP? mice administered aLA-fed mice exhibited improved fasting glucose approaching a high normal level (125 ± 10.6 mg/dl) compared to the pair-fed group (179 ± 15.7 mg/dl) (Fig. 1a) . Fasting insulin levels were also significantly lower in aLA-fed mice (0.96 ± 0.21 ng/ml) than the pairfed group (2.03 ± 0.17 ng/ml) and the ad libitum group (2.23 ± 0.63 ng/ml). Food intake suppression was modest and decreased over time with non-significantly different body weights across groups after 8 weeks of feeding (Ad lib 40.9 ± 1.4 g; Pair-fed 39.8 ± 0.9 g; aLA-fed 38.2 ± 0.8 g). Cholesterol and triglyceride levels were unchanged with aLA feeding. aLA feeding resulted in a significant decrease in serum IL-6 levels (Ad lib 11.9 ± 4.3 ng/ml; Pair-fed 7.4 ± 2.6 ng/ml; aLA-fed 1.1 ± 0.2 ng/ml), an insignificant but measured decrease in MCP-1, and no change in circulating IL-12, TNFa, IFNc, and IL-10 cytokines (Fig. 1c) .
IP aLA Regimen
In contrast to the weight-neutral effects of oral aLA, an IP regimen did have significant weight loss effects. In this experiment as with the oral regimen, after 8 weeks of HFD feeding, mice were randomized to aLA and vehicle control groups. IP aLA resulted in a significant decrease in body weight of 3.9 ± 0.8 g (41.6 ± 0.93 g in IP aLA vs. 45.5 ± 0.73 g in vehicle injected controls). There was no change in plasma total cholesterol but circulating triglycerides were significantly lower in the IP aLA group (59.25 ± 5.7 mg/dl) compared to IP vehicle controls (121 ± 12 mg/dl). IP aLA resulted in significant decreases in serum IL-6, MCP-1, and TNFa. IP aLA also resulted in a significant decrease in serum E-selectin and ICAM-1, markers of monocyte vascular adhesion (Fig. 1d) .
In light of its weight neutral effects we proceeded to investigate oral supplementation of aLA at *160 mg/kg. IP-aLA induced weight loss would have rendered dissociation of weight-loss effects from weight-loss independent effects difficult. Thus continued experimentation focused on the effects of dietary aLA as the effects on food intake Fig. 1 Effect of a-lipoic acid (aLA) on measures of glucose metabolism. a Plasma glucose was measured every 30 min after intra-peritoneal injection of 2 mg/g body weight dextrose after an overnight fast. Fasting glucose and insulin in the aLA-fed mice was significantly lower than the pair-fed control group; *P \ 0.05; **P \ 0.005 aLA-fed group compared to pair-fed (N = 5/group). However, glucose clearance post-bolus was not improved in the aLA group. b IP aLA resulted in significant weight loss, a more dramatic effect on glucose clearance (not shown), and decreased fasting serum triglycerides compared to IP vehicle; **P \ 0.005. Serum cytokines in HFD fed mice receiving either aLA or placebo by drinking water (c) or via intraperitoneal injection (d). Oral aLA resulted in a significant decrease in circulating IL6 levels and a nonsignificant decrease in MCP1; there were no changes in serum IL-12, TNFa, IFNc, and IL-10 cytokine values within the detection the range of the assay. IP aLA administration resulted in a significant decrease in circulating cytokines involved with vascular adhesion and inflammation could be more easily addressed and because aLA is most commonly consumed as a dietary supplement. 
CD11b
? macrophages per gram of epididymal fat from 6.1 9 10 5 ± 0.5 cells per gram in the ad libitum and 7.4 9 10 5 ± 1.7 in the pair fed group to 1.5 9 10 5 ± 0.4 cells per gram in aLA-fed mice (Fig. 2) . This phenomenon was visualized histologically using confocal microscopy of unfixed epididymal adipose collected, stained, and visualized consecutively upon sacrifice. Representative images are provided in Fig. 3a . Assessment of confocal images in the pair-fed mice demonstrate a pattern of crown like structures (CLS) indicative of dead or dying adipocytes [43] and macrophage infiltration. The prevalence of CLS was dramatically decreased in the visceral adipose of the aLA-fed group compared to pair-fed and ad libitum (Fig. 3a) . We then examined CD11c
? cells in the stromal vascular fraction of adipose tissue derived from YFP ? animals. aLA-feed significantly attenuated the number of CD11c
? inflammatory macrophages in the visceral adipose with the ad libitum group containing 1.7 9 10 5 ± 0.4 cells per gram, the pair-fed group 1.5 9 10 5 ± 0.4 cells per gram and the aLA-fed group only 0.4 9 10 5 ± 0.09 cells per gram. To further examine the effect of aLA on monocyte/endothelial interactions and monocyte activation pathways, we tested the effects of aLA on TNFa mediated monocyte adhesion using a model of acute inflammation and additionally tested the effects of aLA on monocyte activation in vitro.
aLA Pretreatment Prevented TNFa-Mediated Vascular Adhesion In Vivo Intravital microscopy of the cremasteric vasculature showed that the number of free-flowing, rolling YFP ? cells was increased by TNFa (Fig. 3b) . While aLA did not have an effect of rolling monocytes, aLA pretreatment significantly prevented TNFa-mediated YFP ? cell adherence to vessel walls suggesting that aLA may modulate adhesion molecules involved in firm monocyte adhesion but not Bone marrow-derived macrophages (BMDM) from wildtype Balb/c mice and toll-like receptor 4 (TLR4) null mice were pretreated with aLA or vehicle control then activated with lipopolysaccharide (LPS), a TLR4 ligand [44] . aLA significantly decreased MCP-1 and TNFa gene expression in response to LPS stimulation but had no effect on IL-6 activation (Fig. 4a) . aLA significantly decreased basal TNFa expression in both TLR4 WT and deficient macrophages. The degree of attenuation of LPS-mediated TNFa expression by aLA alone was small but comparable to that seen with TLR4 def/def . The TNFa and IL-6 response to LPS in TLR4 def/def macrophages was significantly blunted compared to the WT cells. MCP-1 induction by LPS was small compared to TNFa and IL6. LPS-mediated MCP-1 expression, however, was potently inhibited by aLA pretreatment. Interestingly, LPS activation had no effect on CCR2 expression, though aLA significantly down-regulated CCR-2 expression in the presence and absence of LPS; suggesting that non-TLR4 pathways are probably involved in CCR2 down-regulation in response to aLA. aLA increased Mgl1 gene expression, a marker of alternative macrophage activation, while LPS decreased expression (data not shown). These data suggest that aLA may function as an anti-inflammatory agent by preventing inflammatory gene expression. Since nuclear factor kappa B (NF-jB) plays a pivotal role in cellular inflammatory processes we decided to assay the effect of aLA on NF-jB-DNA binding in these TLR WT macrophages. An electrophoretic mobility shift assay showed LPS treatment dramatically increased the binding of NF-jB to the oligonucleotide probe. aLA (100 lg/ml) pretreatment of WT BMDM lead to the inhibition of LPS-mediated (0.5 lg/ml) NF-jB activation as measured by binding to probe DNA.
Discussion
Visceral adipose inflammation is believed to play an etiologic role in the development of insulin resistance (IR) in With accumulation of neutral lipids in the adiposome, adipocytes hypertrophy and a subset undergo ''necrosislike'' cell death resulting in the recruitment of macrophages [45, 46] . The relationship between alterations in innate and adaptive immune cell numbers, their effect on the adipose, and their contribution to the eventual development of obesity is largely attributed to the production and systemic introduction of inflammatory mediators. The pathophysiological processes that develop due to obesity have various putative etiological origins involving multiple tissues, including immune-modulated inflammation of the visceral adipose.
In this study we assessed the effects of aLA on the development of insulin resistance and adipose inflammation in a novel model of murine diet-induced obesity and IR. We demonstrate in pair-feeding experiments that oral aLA exerts beneficial weight loss-independent effects on insulin sensitivity, visceral adipose inflammation, vascular adhesion, and whole body inflammatory cytokine markers. Oral aLA reduced VATM content and activation in insulin resistant, obese mice. aLA also prevented LPS-mediated NF-jB activation and decreased the expression of inflammatory/migratory genes in un-stimulated and LPS-stimulated macrophages. These results suggest that aLA has a potent effect on macrophage activation status and thus may modulate the innate immune response in chronic inflammation in the visceral adipose tissue, a hallmark of type 2 diabetes and the metabolic syndrome.
Though oral aLA was less effective than IP aLA at lowering blood glucose and normalizing markers of insulin resistivity, at the dose used orally, it lacked weight loss effects and obviously prevented its confounding influence in the assessment of results. aLA decreases hypothalamic AMPK activity and causes profound weight loss in rodents by reducing food intake and enhancing energy expenditure [47] . Pair-fed experiments suggest a minimal effect of oral aLA at *160 mg/kg on food intake and body weight over 8 weeks in mice. It should be noted that the first week of oral aLA did result in decreased food intake and some weight loss, however, over the subsequent weeks the effect subsided and weights normalized then increased to levels comparable to controls. The reduction in fasting glucose and insulin by oral aLA did not translate into improved glucose bolus clearance, suggesting that aLA did not abrogate the effects of obesity on glucose metabolism in the long term. However, aLA may selectively regulate fasting indices of glucose homeostasis which have been shown to be sensitive to anti-inflammatory measures [48] . Our data suggest that aLA has a moderate effect in already obese mice. The effect may be more dramatic in mice that begin oral aLA prior to a HFD or in mice that are not already overtly insulin resistant.
The marginal effects of post-prandial indices contrasted dramatically with the ability of aLA to reduce the number and activation status of macrophages in the epididymal adipose. Visceral adipose inflammation is a major area of study in obesity and IR, with visceral adipose inflammation being a putative pathophysiological phenomenon with the activation status of VATM being of particular interest. The phenotypic activation state of macrophages is a crucial determinant of functionality and the inflammatory state. Resident tissue macrophages in lean mice display a phenotype that is typical of cells committed to efferocytosis and scavenger functions and are referred to as M2 or ''alternatively activated'' macrophages expressing antiinflammatory cytokines (Il10, Arginase1, Mgl1) [49] concomitantly with lower levels of M1 genes. High fat diet (HFD) and obesity in mice lead to a M1 or ''classically activated'' state which have been shown to express CD11c and secrete pro-inflammatory cytokines such as TNFa, IL-6, and IL-12 [4] . This phenotypic shift is now believed to play an important role in the genesis of IR [4] . The dramatic attenuation in VATM numbers and CD11c expression observed by aLA is consistent with an effect on activation status of adipose macrophages. Interestingly, the effects of aLA are similar to those reported in obese CCR2 null mice versus obese wild type (WT) mice [13] . Obese CCR2 null mice also showed a reduction in VATM with a modest decrease in whole body insulin resistance. Our data suggest that modulation of VATM activation and visceral infiltration by aLA in already obese mice decreases systemic markers of inflammation and improves markers of insulin sensitivity.
In separate experiments, we addressed the effects of aLA on the monocyte/macrophage activation state and extravasation by demonstrating that acute aLA administration reduced monocyte adhesion to the endothelium. Homing of macrophages to the visceral adipose may be modified by decreasing vascular adhesion, the first step in extravasation and homing to tissue. Our intravital microscopy data demonstrate a dramatic effect of aLA in reducing monocyte adhesion to venules and supports the hypothesis that aLA may reduce monocyte efflux from the vasculature to tissues due to inflammatory signals. Directly measuring monocyte/macrophage efflux to the epididymal adipose is a preferable method but was not technically possible at the time of these mouse experiments.
To further address the role of aLA on TLR4-mediated macrophage activation and signaling we examined the effects of aLA on bone marrow-derived macrophages from TLR4 def/def and WT animals. Recent studies show that the Toll-like receptor 4 (TLR4) may play a central role in the link among insulin resistance, inflammation, and obesity. TLR4 deficiency prevented DIO-mediated insulin resistance and activation of IkB kinase (IKKb) and c-Jun NH2-terminal kinase (JNK), suggesting that TLR4 is a key modulator in the cross-talk between inflammatory and metabolic pathways [18] [19] [20] [21] [22] . Recently it was demonstrated that high fat meals can increase circulating LPS levels and may result from increased intestinal permeability to LPS [50, 51] . Additionally, DIO was shown to induce the expression and activation of TLR4 in the adipose of obese rats, while exercise reduced circulating LPS and TLR4 activation [21] . High levels of saturated NEFA, such as palmitate, when combined with hyperinsulinemia, have been shown to activate human monocytes via TLR4 agonism resulting in the production of pro-inflammatory cytokines [52] . Additionally, high glucose conditions may result in oxidative stress-mediated NF-jB activation and subsequent up-regulation of TNFa and MCP-1 [53, 54] . We demonstrated that aLA was an effective inhibitor of NF-jB activation in murine macrophages, a potent transcription factor regulating inflammatory genes including TNFa and IL6 in this cell. We show that aLA pretreatment is capable of preventing TLR4-mediated up-regulation of MCP-1. MCP-1 is the primary cytokine recruiting monocytes, memory T cells, and dendritic cells to sites of tissue injury and inflammation. It has been shown in endothelial cells that aLA prevented high-glucose induced MCP-1 expression via inhibition of reactive oxygen species-mediated NF-jB activation [54] . The cognate receptor for MCP-1, CCR2 is also down-regulated on monocytes by aLA (albeit via non-TLR4 pathways) suggesting that it may make monocytes less responsive to a MCP-1 chemotactic gradient. Interestingly, CCR2 expression was not induced by TLR4 activation, conversely LPS acted synergistically with aLA to further down-regulate CCR2 expression. aLA also potently decreased LPS-stimulated TNFa gene expression demonstrating that aLA can modulated macrophage activation post TLR4 ligation. These data suggest that aLA is a potent modulator of inflammation via TLR4, non-TLR4 and NF-jB pathways.
We acknowledge several important limitations of this study beginning with our focus on adipose-inflammation centric mechanisms. Our study did not investigate the effects of aLA on hepatic glucose generation or adipocyte function. Prior studies with aLA have clearly demonstrated an effect of aLA in improving serum lactate and pyruvate concentrations and improving glucose levels in lean and obese patients with type 2 diabetes [55] . Our experimental design did not clearly examine the effect of aLA on adipocytes themselves. We cannot say whether aLA decreased visceral adipocyte apoptosis and subsequent VATM infiltration or whether aLA prevented monocyte/macrophage activation and infiltration leading to a lower incidence of adipocyte apoptosis. It is also important to note that aLA may have different mechanisms of action based on duration of treatment, route of administration, and maximal plasma concentration thus comparing data between treatment protocols and in vivo and in vitro results is tenuous and must be taken within context. For example, while aLA potently down-regulated TNF, IL6, and MCP-1 gene expression in vitro, the in vivo effects were not nearly as dramatic in the oral aLA group with only IL-6 being significantly down-regulated and more comparable in the IP-aLA mice. It should also be noted that aLA can activate nuclear factor erythroid2-related factor (Nrf2), the principal transcriptional regulator of antioxidant response element (ARE)-mediated gene expression [56] and through these pathways could exert powerful effects on adipose inflammation [57, 58] . Though prior studies have demonstrated important effects on systemic IR and inflammation, a thorough examination of the long-term weight lossindependent effects of aLA on insulin sensitivity and macrophage activation pathways in already obese individuals was needed.
